Searched for
SUJESH VASUDEVAN
Buy Eris Lifesciences, target price Rs 710: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 7871.82 Crore) operating in Pharmaceutica...- Buy Eris Lifesciences, target price Rs 780: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...
- Glenmark launches COVID-19 drug after DCGI nod; MRP at Rs 103 per tabletThe company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer p...
- HUL to acquire VWash from Glenmark PharmaThe deal includes acquisition of intellectual property rights including trademarks, design and know-how related to the VWash brand, that wa...
- Glenmark Pharma launches anti-diabetes drug Remogliflozin in IndiaGlenmark said it will commercialise Remogliflozin in India under the brand names 'Remo' and 'Remozen'.
- Skin ailments augment derma business in retail pharmaIncreasing incidence of fungal infections, greater awareness of skin-related issues and skin care and a growing desire to look presentable ...
- Glenmark launches Akynzeo in India under licensing pact with HelsinnGlenmark Pharmaceuticals today launched Akynzeo, a drug used for prevention chemotherapy-induced nausea and vomiting, in India and Nepal.
- Glenmark launches biosimilar Adalimumab in IndiaGlenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it t...
- Glenmark Pharmaceuticals launches nicotine gum KwitzKwitz nicotine gum will be available in two variants of 2 mg as an OTC product 4mg as prescription product, the company said in a statement.
- Glenmark launches oral drug for Psoriasis treatment in IndiaThe Mumbai-based company has launched Apremilast under the brand name Aprezo. It has received approval from DCGI for Apremilast after condu...
- Glenmark introduces EMI scheme for cancer treatment drugsAround 12,000 deaths occur due to prostate cancer in the country every year and only about 10-15 per cent patients get complete treatment f...
- China luring Indian pharma scientists with 3 times higher pay to boost formulations segmentThe poaching from across the border could threaten the Indian drug makers and further heat up competition between the two Asian economies.
- Glenmark to launch 10-12 new products in India, eyes 18-20 per cent growthGlenmark Pharmaceuticals proposes to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes...
- Glenmark expecting USFDA nod for 4-6 products this fiscalGlenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (US...
Load More
